Cost cutting and manufacturing in India and China is "compromising drug quality"
This article was originally published in Scrip
Executive Summary
Cost containment and price squeezes are jeopardising the quality of medicines, particularly if these measures mean that payers are increasingly buying low-cost drugs produced in India and China, warned delegates at the 51st annual GIRP (full-line wholesalers organisation) meeting in Cannes this week.